Accelerated vs. Standard Chemotherapy for Metastatic Germ Cell Tumors
This study is comparing two ways of giving chemotherapy for metastatic germ cell tumors (a type of cancer that starts in reproductive cells). It's testing if an "accelerated" schedule of Bleomycin, Etoposide, and Cisplatin, along with Pegylated G-CSF or Filgrastim (medications to help with side effects), works better than the standard schedule. The study aims to enroll 500 patients aged 11 to 50 years old who have intermediate or poor-risk metastatic germ cell tumors. Researchers will measure how long patients live without their disease getting worse or until death, for up to 5 years. The current status of this study is unclear.
- Study design
- This interventional study plans to enroll 500 participants and compares two different chemotherapy schedules.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progression-free survival (time until disease progression or death) will be assessed for up to 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
At a glance
Conditions
Where it's being run
28 sites across 10 statesStudy leadership
- Peter Grimison · STUDY_CHAIR · Chris O'Brien Lifehouse
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression-free survival (disease progression or death)From randomisation up to disease progression or date of death whichever come first, assessed up to 5 years
PFS is measured from the date of randomisation until the criteria for disease progression are met (as defined in the protocol) or death. Participants who are not observed to progress nor die will be censored at the date of last follow-up